YahooSeptember 11, 2026 at 1:35 AM NYLast Month
Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply
On August 11, Zura Bio (NASDAQ:ZURA) reported second-quarter results that landed on an unusual mix of good and bad news. The clinical-stage biotech finished enrolling two separate Phase 2 studies of its lead drug, tibulizumab, both ahead of their original targets, while a widening net loss showed just how much it costs to run them. […]
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
